REV1

Summary

REV1 (REV1 DNA directed polymerase, HGNC:14060) is a protein-coding gene on chromosome 2q11.2, encoding Translesion synthesis protein REV1 (Q9UBZ9). Bifunctional protein involved in the maintenance of genome stability through translesion DNA synthesis (TLS) and antibody diversification via somatic hypermutation.

This gene encodes a protein with similarity to the S. cerevisiae mutagenesis protein Rev1. The Rev1 proteins contain a BRCT domain, which is important in protein-protein interactions. A suggested role for the human Rev1-like protein is as a scaffold that recruits DNA polymerases involved in translesion synthesis (TLS) of damaged DNA.

Source: NCBI Gene 51455 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 176 total
• Druggable target: yes
• MANE Select transcript: NM_016316

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14060
Approved symbol	REV1
Name	REV1 DNA directed polymerase
Location	2q11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000135945
Ensembl biotype	protein_coding
OMIM	606134
Entrez	51455

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 17 protein_coding, 7 retained_intron, 4 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000258428, ENST00000393445, ENST00000413697, ENST00000438366, ENST00000450415, ENST00000465086, ENST00000465835, ENST00000472000, ENST00000473819, ENST00000477121, ENST00000481719, ENST00000482595, ENST00000482887, ENST00000485487, ENST00000486117, ENST00000491752, ENST00000879663, ENST00000879664, ENST00000879665, ENST00000879666, ENST00000920275, ENST00000920276, ENST00000920277, ENST00000920278, ENST00000920279, ENST00000920280, ENST00000920281, ENST00000949065, ENST00000949066, ENST00000949067

RefSeq mRNA: 7 — MANE Select: NM_016316 NM_001037872, NM_001321454, NM_001321455, NM_001321458, NM_001321459, NM_001321460, NM_016316

CCDS: CCDS2045, CCDS42722

Canonical transcript exons

ENST00000258428 — 23 exons

Exon	Start	End
ENSE00000921841	99402244	99402346
ENSE00000921842	99402644	99402800
ENSE00000921860	99462496	99462622
ENSE00000921861	99464922	99464985
ENSE00003465659	99412731	99412951
ENSE00003481228	99424152	99424280
ENSE00003486913	99406325	99406490
ENSE00003504454	99403695	99403815
ENSE00003512735	99404444	99404677
ENSE00003512891	99418828	99418947
ENSE00003546405	99434332	99434448
ENSE00003573701	99438601	99439310
ENSE00003583000	99402889	99403106
ENSE00003606983	99410695	99410867
ENSE00003639764	99429840	99429948
ENSE00003639967	99421499	99421653
ENSE00003644262	99405910	99406106
ENSE00003655281	99435834	99435941
ENSE00003666394	99449336	99449504
ENSE00003677608	99442317	99442469
ENSE00003679916	99408029	99408131
ENSE00003845193	99400477	99401352
ENSE00003846929	99489817	99490017

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 97.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.6764 / max 446.2443, expressed in 1772 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29884	10.6764	1772

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.63	gold quality
oocyte	CL:0000023	97.51	gold quality
calcaneal tendon	UBERON:0003701	96.79	gold quality
cerebellar hemisphere	UBERON:0002245	96.45	gold quality
cerebellar cortex	UBERON:0002129	96.42	gold quality
cerebellum	UBERON:0002037	96.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.12	gold quality
adrenal tissue	UBERON:0018303	96.09	gold quality
right uterine tube	UBERON:0001302	95.47	gold quality
ectocervix	UBERON:0012249	94.35	gold quality
mucosa of stomach	UBERON:0001199	94.30	gold quality
skin of abdomen	UBERON:0001416	94.05	gold quality
body of uterus	UBERON:0009853	94.05	gold quality
left ovary	UBERON:0002119	94.04	gold quality
cortical plate	UBERON:0005343	94.03	gold quality
right lung	UBERON:0002167	93.97	gold quality
tibia	UBERON:0000979	93.91	gold quality
skin of leg	UBERON:0001511	93.85	gold quality
vagina	UBERON:0000996	93.66	gold quality
metanephros cortex	UBERON:0010533	93.61	gold quality
right ovary	UBERON:0002118	93.60	gold quality
left uterine tube	UBERON:0001303	93.56	gold quality
diaphragm	UBERON:0001103	93.51	gold quality
corpus callosum	UBERON:0002336	93.48	gold quality
endocervix	UBERON:0000458	93.47	gold quality
pituitary gland	UBERON:0000007	93.39	gold quality
minor salivary gland	UBERON:0001830	93.39	gold quality
lower esophagus mucosa	UBERON:0035834	93.32	gold quality
upper lobe of left lung	UBERON:0008952	93.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.23	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.13
E-MTAB-6379	no	593.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting REV1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-96-5P	99.95	72.80	2140
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889

Literature-anchored findings (GeneRIF, showing 40)

• purified human REV1 and REV7 proteins form a heterodimer in solution, which is stable through intensive purification steps. (PMID:12529368)
• UV-induced mutant frequencies at the HPRT locus were reduced up to 75% in cells with reduced levels of REV1 mRNA and data support that targeting the mutagenic translesion DNA replication pathway can greatly reduce the frequency of induced mutations. (PMID:12930947)
• REV1 interacts with three Y-family DNA polymerases. (PMID:15189446)
• REV1 interacts with pol eta in translesion synthesis of damaged DNA (PMID:15380106)
• REV1-dependent processes are important determinants of cisplatin-induced genomic instability and the development of resistance. (PMID:16495473)
• a novel biochemical activity of human REV1 protein, due to higher affinity for single-stranded DNA (ssDNA) than the primer terminus (PMID:16803901)
• Rev1 is a polypeptide associated with Poleta. The study results suggest that arrested replication forks strengthen interactions among Poleta, Rad18/Rad6 and Rev1, consistent with the requirement for effective TLS by Poleta at sites of DNA lesions. (PMID:16824193)
• Results support Phe257Ser and Ser257Ser genotypes are associated with a decreased risk for cervical carcinoma, while Asn373Ser and Ser373Ser genotypes increased the risk. (PMID:18470628)
• Data show that PCNA ubiquitination and REV1 play distinct roles in the coordination of DNA damage bypass that are temporally separated relative to replication fork arrest. (PMID:18498753)
• human REV1, apparently the slowest Y family polymerase, is kinetically highly tolerant to N(2)-adduct at G but not to O(6)-adducts. (PMID:18591245)
• plays a role in mutagenesis and translesin DNA synthesis. (review) (PMID:18975621)
• Poleta-REV1 interactions prevent spontaneous mutations, probably by promoting accurate translesion DNA synthesis past endogenous DNA lesions (PMID:19157994)
• Novel structural features are important for providing Rev1 greater latitude in promoting efficient and error-free translesion DNA synthesis through the diverse array of bulky and potentially carcinogenic N(2)-deoxyguanosine DNA adducts in human cells. (PMID:19464298)
• Translesional DNA synthesis through a C8-guanyl adduct of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in Vitro: REV1 inserts dC opposite the lesion, and DNA polymerase kappa potentially catalyzes extension reaction from the 3’-dC terminus. (PMID:19628463)
• REV1 and Polzeta facilitate repair of interstrand cross-links independently of PCNA monoubiquitination and Poleta, whereas RAD18 plus Poleta, REV1, and Polzeta are all necessary for replicative bypass of cisplatin intrastrand DNA cross-links. (PMID:20028736)
• The results suggest that the positive charge on R357 could prevent interaction of REV1 with dGTP. (PMID:20059978)
• the interaction between REV7 and REV3 creates a structural interface for REV1 binding (PMID:20164194)
• WRN facilitates REV1-dependent translesion synthesis. (PMID:20691646)
• Results suggest that abasic sites might be bypassed by single B- and Y-family pols or combinations, possibly by REV1 and pols iota, eta, and delta/PCNA at the insertion step opposite the lesion and by pols eta and delta/PCNA at the subsequent extension step. (PMID:20888339)
• Hsp90 promotes folding of REV1 into a stable and/or functional form(s) to bind to monoubiquitinated proliferating cell nuclear antigen in the regulation of translesion DNA synthesis-mediated mutagenesis (PMID:21690293)
• The REV1/Polzeta complex maintains genomic stability by directly participating in DNA double-stranded break repair. (PMID:21926160)
• FAAP20 binding stabilizes Rev1 nuclear foci and promotes interaction of the Fanconi anemia core with PCNA-Rev1 DNA damage bypass complexes. (PMID:22266823)
• REV7 subunit of pol zeta mediated the interaction between REV3 and the REV1 C terminus. (PMID:22303021)
• a structural basis for understanding the recognition of the Rev1-CT by Y-family DNA polymerases (PMID:22691049)
• Findings indicate that miR-96 regulates DNA repair and chemosensitivity by repressing RAD51 and REV1. (PMID:22761336)
• the Rev1 C-terminal domain utilizes independent interaction interfaces to simultaneously bind a fragment of the ‘inserter’ poleta and Rev7 subunit of the ’extender’ polvarsigma, thereby serving as a cassette that may accommodate several polymerases (PMID:22828282)
• analysis of the crystal structure of the ternary complex composed of the C-terminal domain of human REV1, REV7, and a REV3 fragment (PMID:22859296)
• ternary complex of the C-terminal domain of human REV1 in complex with REV7 bound to a REV3 fragment has been crystallized. The crystals belonged to space group P3(1)21, with unit-cell parameters a = b = 74.7, c = 124.5 A (PMID:22869133)
• the first structural insights into the regulation of human Rev1 for TLS polymerases. (PMID:23220741)
• Rev1 but not Poleta depletion is epistatic to the lack of PCNA ubiquitination. (PMID:23761444)
• The results show that human Rev1 disrupts G4 DNA structures and prevents refolding in vitro. (PMID:24366879)
• Structural studies suggest the possible involvement of XRCC1 and its associated repair factors, REV1 in post replication repair. (PMID:24409475)
• Our results suggest for the first time that REV1 and REV3L SNPs might serve as potential predictive markers of outcome of cisplatin-based chemotherapy (PMID:24956248)
• The molecular mechanism of 3-nitrobenzanthrone genotoxicity in HEK293 cells is reported. (PMID:25080294)
• show that REV1 is a novel binding partner of the tumor suppressor p53 and regulates its activity (PMID:25614517)
• Data suggest Rev1 protein recognition mechanism by Fanconi anemia-associated protein 20 (FAAP20). (PMID:26318859)
• Rev1 is indispensable for Translesion synthesis mediated by Poleta, Poliota, and Polkappa but is not required for TLS by Polzeta. (PMID:26680302)
• REV1 can promote PCNA monoubiquitylation after UV radiation through interacting with ubiquitylated RAD18. (PMID:26795561)
• Saccharomyces cerevisiae (PMID:26903512)
• the catalytic function of REV1 is moderately or slightly altered by at least nine genetic variations, and the G4 DNA processing function of REV1 is slightly enhanced by the N373S variation, which might provide the possibility that certain germline missense REV1 variations affect the individual susceptibility to carcinogenesis by modifying the capability of REV1 for replicative bypass past DNA lesions and G4 motifs derived (PMID:26914252)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rev1	ENSDARG00000018296
mus_musculus	Rev1	ENSMUSG00000026082
rattus_norvegicus	Rev1	ENSRNOG00000018623
drosophila_melanogaster	Rev1	FBGN0035150
caenorhabditis_elegans		WBGENE00014066

Paralogs (5): POLI (ENSG00000101751), POLK (ENSG00000122008), ESCO1 (ENSG00000141446), POLH (ENSG00000170734), ESCO2 (ENSG00000171320)

Protein

Protein identifiers

Translesion synthesis protein REV1 — Q9UBZ9 (reviewed: Q9UBZ9)

Alternative names: Alpha integrin-binding protein 80, Molecular adapter protein REV1, Rev1-like terminal deoxycytidyl transferase, Reversionless protein 1 homolog, Template-dependent deoxycytidyl transferase REV1

All UniProt accessions (4): C9JPS2, Q9UBZ9, F8WCR0, H7C263

UniProt curated annotations — full annotation on UniProt →

Function. Bifunctional protein involved in the maintenance of genome stability through translesion DNA synthesis (TLS) and antibody diversification via somatic hypermutation. Functions as a molecular adapter protein at stalled DNA replication, coordinating polymerases recruitment, selection, and switching, in a manner independent of its deoxycytidyl transferase activity. At the site of DNA lesion, recruits and mediates the switch between low-fidelity inserter DNA polymerases, such as POLK, that incorporate nucleotides opposite lesions and the extender DNA polymerase zeta complex which continues DNA synthesis from distorted primer termini. In vitro, acts as a template-dependent deoxycytidyl transferase that preferentially incorporates deoxycytidine residues from dCTP to the 3’-end of a DNA primer opposite apurinic/apyrimidinic (AP) site, uracil, undamaged DNA templates (G > A > C > T) and a variety of damaged DNA templates. Opposite template guanine, efficiently incorporates not only dCMP but also non-complementary dGMP and dTMP, with lower efficiency for dAMP, demonstrating low fidelity on undamaged DNA. This catalytic activity has been implicated in somatic hypermutation, likely achieved by incorporation of deoxycytidine opposite abasic sites, generated at cytidines via activation-induced deoxycytidine deaminase (AID)-mediated deamination and uracil DNA glycosylase (UNG) activity, respectively. In addition, exhibits a 5’-deoxyribose-5-phosphate lyase activity in vitro, though its necessity in vivo is not confirmed.

Subunit / interactions. Monomer. Homodimer. Homotetramer. Interacts (via C-terminal domain) with the DNA polymerase zeta complex which is composed of REV3L and MAD2L2; the interaction with MAD2L2 is direct, and REV3L forms and stabilizes the DNA polymerase zeta complex before being recruited by REV1 to the DNA lesion site. Forms a quaternary complex with POLK, MAD2L2 and REV3L, where REV3L-bound MAD2L2 and POLK are able to bind simultaneously to REV1 forming the stable translesion synthesis (TLS) machinery therefore bridging the inserter and extender polymerases. May bind ITGA3. Interacts with FAAP20 (via UBZ2-type zinc finger); this interaction contributes to the stable association of the two proteins in nuclear foci in response to replication stress. Interacts (via C-terminal domain) with POLH. Interacts (via C-terminal domain) with POLD3. Interacts with UBB. Interacts (via C-terminal domain) with POLK; POLK competes with MAD2L2 for binding to REV1. Interacts (via C-terminal domain) with POLI. Interacts (via BRCT domain) with PCNA; this interaction is enhanced with a monoubiquitinated form of PCNA and mediates the recruitment of REV1 to stalled DNA replication.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous.

Post-translational modifications. Monoubiquitinated. Undergoes a ubiquitination-deubiquitination cycle. The monoubiquitination is not required for FAAP20 interaction but enhances it, contributing to the stable association of the two proteins at DNA lesions in response to replication stress.

Domain organisation. The C-terminal domain mediates interaction with the major translesion synthesis (TLS) polymerases, POLH, POLI, and POLK, and the adapter subunit MAD2L2 of DNA polymerase zeta complex and is essential for tolerance of DNA damage caused by a number of mutagens. The C-terminal domain can binds simultaneously both POLK and the MAD2L2 subunit of DNA polymerase zeta complex, bridging the inserter and extender polymerases during TLS. The BRCT domain promotes resistance to DNA damage by mediating interaction with PCNA and localization to nuclear foci. Ubiquitin-binding motif (UBM) domains contribute to DNA damage tolerance and damage-induced mutagenesis by enhancing both REV1’s interaction with monoubiquitinated PCNA and association with replication foci. Only the UBM2 domain mediates UBB binding.

Similarity. Belongs to the DNA polymerase type-Y family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UBZ9-1	1, REV1	yes
Q9UBZ9-2	2, REV1S
Q9UBZ9-3	3

RefSeq proteins (7): NP_001032961, NP_001308383, NP_001308384, NP_001308387, NP_001308388, NP_001308389, NP_057400* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001126	UmuC	Domain
IPR001357	BRCT_dom	Domain
IPR012112	REV1	Family
IPR017961	DNA_pol_Y-fam_little_finger	Domain
IPR025527	HUWE1/Rev1_UBM	Conserved_site
IPR031991	Rev1_C	Domain
IPR036420	BRCT_dom_sf	Homologous_superfamily
IPR036775	DNA_pol_Y-fam_lit_finger_sf	Homologous_superfamily
IPR038401	Rev1_C_sf	Homologous_superfamily
IPR043128	Rev_trsase/Diguanyl_cyclase	Homologous_superfamily
IPR043502	DNA/RNA_pol_sf	Homologous_superfamily
IPR047346	Rev1_UBM1/2	Conserved_site
IPR053848	IMS_HHH_1	Domain

Pfam: PF00533, PF00817, PF11799, PF14377, PF16727, PF21999

Catalyzed reactions (Rhea), 1 shown:

• DNA(n) + dCTP = DNA(n)-C + diphosphate (RHEA:86319)

UniProt features (137 total): helix 38, binding site 23, strand 19, sequence variant 16, mutagenesis site 9, turn 7, compositionally biased region 6, region of interest 5, domain 4, splice variant 4, active site 3, chain 1, short sequence motif 1, site 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
4EXT	X-RAY DIFFRACTION	1.9
6WS0	X-RAY DIFFRACTION	2.24
6ASR	X-RAY DIFFRACTION	2.36
6WS5	X-RAY DIFFRACTION	2.47
3GQC	X-RAY DIFFRACTION	2.5
4GK0	X-RAY DIFFRACTION	2.7
9VGW	X-RAY DIFFRACTION	2.7
4BA9	X-RAY DIFFRACTION	2.73
3VU7	X-RAY DIFFRACTION	2.8
4GK5	X-RAY DIFFRACTION	3.21
2EBW	SOLUTION NMR
2LSI	SOLUTION NMR
2LSK	SOLUTION NMR
2LSY	SOLUTION NMR
2N1G	SOLUTION NMR
5VZM	SOLUTION NMR
6AXD	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBZ9-F1	67.20	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 423; 570; 571; 428 (substrate discrimination)

Ligand- & substrate-binding residues (23): 357; 423; 424; 424; 426; 427; 428; 510; 513; 516; 522; 570 …

Mutagenesis-validated functional residues (9):

Position	Phenotype
570–571	loss of deoxycytidyl transferase activity.
570	abolishes transferase activity; when associated with a-571.
571	abolishes transferase activity; when associated with a-570.
946	loss of monoubiquitination; when associated with a-947, a-1024 and a-1025.
947	loss of monoubiquitination; when associated with a-946, a-1024 and a-1025.
958	does not affect ubb binding; when associated with a-977.
977	does not affect ubb binding; when associated with a-977.
1024	loss of monoubiquitination; when associated with a-946, a-947 and a-1025.
1025	loss of monoubiquitination; when associated with a-946, a-947 and a-1024.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-110312	Translesion synthesis by REV1
R-HSA-5655862	Translesion synthesis by POLK
R-HSA-5656121	Translesion synthesis by POLI
R-HSA-5656169	Termination of translesion DNA synthesis

MSigDB gene sets: 164 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_DNA_DAMAGE_TOLERANCE, KAUFFMANN_DNA_REPAIR_GENES, GTACAGG_MIR486, GOCC_NUCLEAR_REPLICATION_FORK, CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP, GOBP_ERROR_FREE_TRANSLESION_SYNTHESIS, GOMF_DNA_POLYMERASE_ACTIVITY, GOBP_IMMUNOGLOBULIN_PRODUCTION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_SOMATIC_DIVERSIFICATION_OF_IMMUNE_RECEPTORS, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, GOBP_DNA_BIOSYNTHETIC_PROCESS, HIF1_Q3, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN

GO Biological Process (10): DNA repair (GO:0006281), somatic hypermutation of immunoglobulin genes (GO:0016446), translesion synthesis (GO:0019985), error-prone translesion synthesis (GO:0042276), error-free translesion synthesis (GO:0070987), DNA biosynthetic process (GO:0071897), DNA metabolic process (GO:0006259), DNA replication (GO:0006260), DNA damage response (GO:0006974), response to UV (GO:0009411)

GO Molecular Function (11): DNA binding (GO:0003677), damaged DNA binding (GO:0003684), DNA-directed DNA polymerase activity (GO:0003887), deoxycytidyl transferase activity (GO:0017125), protein-macromolecule adaptor activity (GO:0030674), ubiquitin binding (GO:0043130), metal ion binding (GO:0046872), DNA-(abasic site) binding (GO:0140431), protein binding (GO:0005515), transferase activity (GO:0016740), nucleotidyltransferase activity (GO:0016779)

GO Cellular Component (4): nucleoplasm (GO:0005654), nuclear replication fork (GO:0043596), site of DNA damage (GO:0090734), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	4

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	3
translesion synthesis	2
cellular anatomical structure	2
DNA damage response	1
somatic diversification of immune receptors via somatic mutation	1
somatic diversification of immunoglobulins	1
DNA damage tolerance	1
DNA synthesis involved in DNA replication	1
nucleic acid biosynthetic process	1
nucleic acid metabolic process	1
DNA biosynthetic process	1
cellular response to stress	1
response to light stimulus	1
nucleic acid binding	1
DNA binding	1
DNA polymerase activity	1
nucleotidyltransferase activity	1
protein binding	1
molecular adaptor activity	1
ubiquitin-like protein binding	1
cation binding	1
damaged DNA binding	1
binding	1
catalytic activity	1
transferase activity, transferring phosphorus-containing groups	1
nuclear lumen	1
nuclear chromosome	1
nucleus	1
replication fork	1
CMG complex	1
chromosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2080 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
REV1	MAD2L2	Q9UI95	999
REV1	REV3L	O60673	999
REV1	POLM	Q9NP87	992
REV1	POLL	Q9UGP5	961
REV1	UNG	P13051	899
REV1	RAD18	Q9NS91	846
REV1	POLD2	P49005	828
REV1	UBE2V2	Q15819	818
REV1	POLD3	Q15054	800
REV1	UBE2N	P61088	783
REV1	POLH	Q9Y253	775
REV1	FANCD2	Q9BXW9	773
REV1	F6S8H2	F6S8H2	754
REV1	OGG1	P78554	742
REV1	LIG1	P18858	738

IntAct

14 interactions, top by confidence:

A	B	Type	Score
MAD2L2	REV3L	psi-mi:“MI:0915”(physical association)	0.640
REV1	FAAP20	psi-mi:“MI:0407”(direct interaction)	0.540
REV1	FAAP20	psi-mi:“MI:0915”(physical association)	0.540
FHL2	REV1	psi-mi:“MI:0915”(physical association)	0.510
REV1	FHL2	psi-mi:“MI:0915”(physical association)	0.510
POLH	REV1	psi-mi:“MI:0407”(direct interaction)	0.440
REV1	TUFM	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
GPKOW	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
RPS11	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (98): REV1 (Affinity Capture-MS), REV1 (Co-crystal Structure), REV1 (Biochemical Activity), PIAS4 (Affinity Capture-Western), TP53 (Affinity Capture-Western), PCNA (Affinity Capture-Western), Mad2l2 (Affinity Capture-Western), REV1 (Affinity Capture-Western), REV1 (Affinity Capture-Western), REV1 (Reconstituted Complex), REV1 (Two-hybrid), REV1 (Affinity Capture-Western), FHL2 (Affinity Capture-Western), REV1 (Reconstituted Complex), REV1 (Two-hybrid)

ESM2 similar proteins: D4A6L0, F1M5F3, F1N2W9, F1QDI9, F6RIX4, I0IUP4, O75808, P22681, P22682, P55266, Q14432, Q15047, Q2KHI9, Q3U269, Q496Y0, Q4KWZ7, Q52L14, Q5C9Z4, Q5R4N7, Q5R6Z9, Q5RCP1, Q5T7W7, Q5T848, Q5XIX3, Q62865, Q642B6, Q66JB6, Q69ZT1, Q6NRM6, Q6P3Z3, Q7TPQ3, Q8BUM9, Q8HXH0, Q8IYL2, Q8K214, Q8K2I9, Q8K4J0, Q8NFZ0, Q8WY91, Q920Q2

Diamond homologs: A0Q6K9, A1A7U2, A1KUQ3, A1RMZ5, A1S8M3, A2RNH9, A3EWL3, A3N148, A3QGY9, A4TPK8, A4W6W8, A5IH02, A5IU61, A6QIC3, A6U2Z9, A6VA50, A7MEN4, A7NC07, A7X420, A7ZHZ2, A7ZWJ6, A8AKQ2, A8FYV3, A8GAC8, A8H771, A9MNS1, A9MY13, B0BPX9, B0TQD1, B0TZS5, B1J100, B1KD33, B2FLR2, B2SH34, B2U3S3, B2UKN1, B4SIF5, B8F542, B9DMT3, P58963

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CDC20	“down-regulates quantity by destabilization”	REV1	binding
FZR1	“down-regulates quantity by destabilization”	REV1	binding
APC-c	“down-regulates quantity by destabilization”	REV1	polyubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

176 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	137
Likely benign	11
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4190 predictions. Top by Δscore:

Variant	Effect	Δscore
2:99401348:TCAGC:T	acceptor_gain	1.0000
2:99401349:CAGC:C	acceptor_gain	1.0000
2:99401349:CAGCC:C	acceptor_gain	1.0000
2:99401350:AGCC:A	acceptor_loss	1.0000
2:99401352:CCTAA:C	acceptor_loss	1.0000
2:99401353:C:CC	acceptor_gain	1.0000
2:99401353:CT:C	acceptor_loss	1.0000
2:99401354:T:C	acceptor_loss	1.0000
2:99402238:TACTA:T	donor_loss	1.0000
2:99402241:TAC:T	donor_loss	1.0000
2:99402242:ACCTT:A	donor_loss	1.0000
2:99402243:C:T	donor_loss	1.0000
2:99402347:C:CC	acceptor_gain	1.0000
2:99403683:T:TA	donor_gain	1.0000
2:99403815:CC:C	acceptor_loss	1.0000
2:99403815:CCTAG:C	acceptor_gain	1.0000
2:99403816:C:CA	acceptor_loss	1.0000
2:99403819:G:C	acceptor_gain	1.0000
2:99403819:G:GC	acceptor_gain	1.0000
2:99404439:CTTA:C	donor_loss	1.0000
2:99404440:TTAC:T	donor_loss	1.0000
2:99404441:TA:T	donor_loss	1.0000
2:99404442:A:AC	donor_gain	1.0000
2:99404443:C:CA	donor_loss	1.0000
2:99404443:C:CC	donor_gain	1.0000
2:99404674:CCAG:C	acceptor_gain	1.0000
2:99404675:CAGC:C	acceptor_gain	1.0000
2:99404678:C:CC	acceptor_gain	1.0000
2:99406000:AG:A	donor_gain	1.0000
2:99406105:TA:T	acceptor_gain	1.0000

AlphaMissense

8229 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:99401324:A:G	W1225R	1.000
2:99401324:A:T	W1225R	1.000
2:99402298:A:G	L1197P	1.000
2:99402662:A:G	W1175R	1.000
2:99402662:A:T	W1175R	1.000
2:99449349:A:G	W113R	1.000
2:99449349:A:T	W113R	1.000
2:99401290:A:T	V1236D	0.999
2:99401299:A:G	L1233P	0.999
2:99401304:A:C	F1231L	0.999
2:99401304:A:T	F1231L	0.999
2:99401306:A:G	F1231L	0.999
2:99401322:C:A	W1225C	0.999
2:99401322:C:G	W1225C	0.999
2:99402271:A:G	L1206P	0.999
2:99402308:A:G	C1194R	0.999
2:99402311:A:C	Y1193D	0.999
2:99402331:T:G	D1186A	0.999
2:99402332:C:G	D1186H	0.999
2:99402343:G:T	P1182Q	0.999
2:99402660:C:A	W1175C	0.999
2:99402660:C:G	W1175C	0.999
2:99402670:A:G	L1172P	0.999
2:99402709:A:G	L1159P	0.999
2:99403790:A:G	L1024P	0.999
2:99403790:A:T	L1024H	0.999
2:99412816:C:G	R696P	0.999
2:99449402:A:G	L95P	0.999
2:99449411:G:T	A92D	0.999
2:99462510:A:T	V56D	0.999

dbSNP variants (sampled 300 via entrez): RS1000025189 (2:99473867 A>G), RS1000030994 (2:99434539 G>A,C,T), RS1000075241 (2:99491132 A>G), RS1000107181 (2:99480539 A>C,G), RS1000127959 (2:99451028 T>C,G), RS1000147496 (2:99462945 G>A), RS1000167264 (2:99438583 A>G), RS1000174640 (2:99481919 G>C), RS1000231138 (2:99402042 T>C,G), RS1000240863 (2:99401781 T>C), RS1000292705 (2:99468160 A>C,G), RS1000305520 (2:99444390 C>T), RS1000409 (2:99441727 A>G,T), RS1000421326 (2:99418561 T>C), RS1000434346 (2:99408493 C>T)

Disease associations

OMIM: gene MIM:606134 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001241_13	Bipolar disorder	3.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295973 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3087403	Efficacy	3	cisplatin	Osteosarcoma

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3087386	REV1		0.00	0
rs3087399	REV1		0.00	0
rs3087403	REV1	3	2.75	1	cisplatin

ChEMBL bioactivities

38 potent at pChembl≥5 of 63 total, top 38 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.70	Ki	2000	nM	CHEMBL4240676
5.68	Kd	2100	nM	CHEMBL4240676
5.60	IC50	2500	nM	CHEMBL4238011
5.60	IC50	2500	nM	CHEMBL4249624
5.60	IC50	2500	nM	CHEMBL4240676
5.54	Kd	2900	nM	CHEMBL1717725
5.52	Ki	3000	nM	CHEMBL1717725
5.46	IC50	3500	nM	CHEMBL1717725
5.46	Kd	3500	nM	CHEMBL4245882
5.44	Ki	3600	nM	CHEMBL4245882
5.44	Kd	3600	nM	CHEMBL4246571
5.44	Ki	3600	nM	CHEMBL1721787
5.44	Kd	3600	nM	CHEMBL1721787
5.43	Kd	3700	nM	CHEMBL4249812
5.39	IC50	4100	nM	CHEMBL4245882
5.37	Kd	4300	nM	CHEMBL4237457
5.36	Kd	4400	nM	CHEMBL4249624
5.34	IC50	4600	nM	CHEMBL4237457
5.34	Ki	4600	nM	CHEMBL4249624
5.34	IC50	4600	nM	CHEMBL4244874
5.33	Ki	4700	nM	CHEMBL4237457
5.32	Ki	4800	nM	CHEMBL4249812
5.31	IC50	4900	nM	CHEMBL4241371
5.31	Ki	4900	nM	CHEMBL4246571
5.26	IC50	5500	nM	CHEMBL1721787
5.23	IC50	5900	nM	CHEMBL4238016
5.23	IC50	5900	nM	CHEMBL4246571
5.21	IC50	6200	nM	CHEMBL4249812
5.19	Kd	6500	nM	CHEMBL4238011
5.17	Kd	6700	nM	CHEMBL4245882
5.16	Ki	6900	nM	CHEMBL4238011
5.16	Kd	6900	nM	CHEMBL4244874
5.13	Ki	7400	nM	CHEMBL4244254
5.11	Kd	7800	nM	CHEMBL4238016
5.09	Kd	8200	nM	CHEMBL4244254
5.05	Ki	8900	nM	CHEMBL4244874
5.03	IC50	9400	nM	CHEMBL4244254
5.02	Kd	9500	nM	CHEMBL4241371

PubChem BioAssay actives

38 with measured affinity, of 127 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
8-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-1,3-dimethyl-7-(3-oxobutan-2-yl)purine-2,6-dione	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ki	2.0000	uM
1-acetyl-N-[3-(cyclopropylcarbamoyl)-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]piperidine-4-carboxamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ic50	2.5000	uM
N-(4-ethylphenyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]acetamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ic50	2.5000	uM
(4-methyl-3-morpholin-4-ylsulfonylphenyl)-(4-phenylpiperazin-1-yl)methanone	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	kd	2.9000	uM
methyl 2-[(1-acetylpiperidine-4-carbonyl)amino]-5-propylthiophene-3-carboxylate	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	kd	3.5000	uM
N-(4-ethylphenyl)-2-[4-(4-methoxyphenyl)piperazin-1-yl]acetamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ki	3.6000	uM
1-(4-butylphenyl)-N-(1,1-dioxothiolan-3-yl)-N,5-dimethyltriazole-4-carboxamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	kd	3.6000	uM
[4-[4-(2,5-dimethoxyphenyl)-1,3-thiazol-2-yl]piperazin-1-yl]-(furan-2-yl)methanone	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	kd	3.7000	uM
N-[4-[4-(2-methoxyphenyl)piperazine-1-carbonyl]phenyl]-N-methylethanesulfonamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	kd	4.3000	uM
4-acetyl-N-(9-ethylcarbazol-3-yl)piperidine-1-carboxamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ic50	4.6000	uM
1-acetyl-N-(3-carbamoyl-6-propyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)piperidine-4-carboxamide	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ic50	4.9000	uM
ethyl 2-[(1-acetylpiperidine-4-carbonyl)amino]-5-propylthiophene-3-carboxylate	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ic50	5.9000	uM
methyl 2-[(1-acetylpiperidine-4-carbonyl)amino]-5-methylthiophene-3-carboxylate	1398243: Displacement of FAM-labelled polkappa-RIR peptide from recombinant human C-terminal Rev1 (1158 to 1251 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by fluorescence polarization assay	ki	7.4000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation	3
sodium arsenite	decreases expression, increases abundance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cadmium Chloride	decreases expression, affects expression, increases abundance	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
myristicin	decreases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
quinoline yellow	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
bisphenol S	decreases methylation	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Cadmium	increases abundance, affects expression	1
Caffeine	increases phosphorylation	1
Coal	decreases expression, increases abundance	1
Demecolcine	decreases expression	1
Doxorubicin	decreases expression, affects expression, affects response to substance	1
Erythrosine	decreases expression	1
Fluorouracil	affects expression	1
Formaldehyde	decreases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4222910	Binding	Binding affinity to recombinant human REV1 UBM1/UBM2 domain (137 residues) expressed in Escherichia coli BL21(DE3) assessed as increase in NOE peaks at 200 uM by STD NMR spectral analysis	Small-molecules that bind to the ubiquitin-binding motif of REV1 inhibit REV1 interaction with K164-monoubiquitinated PCNA and suppress DNA damage tolerance. — Bioorg Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1R10	HCT116-REV1(+/-)	Cancer cell line	Male
CVCL_1R11	HCT116-REV1(-/-)	Cancer cell line	Male
CVCL_D8UK	Ubigene HCT 116 REV1 KO	Cancer cell line	Male
CVCL_TI85	HAP1 REV1 (-) 1	Cancer cell line	Male
CVCL_TI86	HAP1 REV1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial